Clinical Research in Oncology

Perspective Open Access

Measurable residual disease as a surrogate endpoint for overall survival in acute myeloid leukemia: a call to action

Marie-Helene Blanchet Zumofen , Vicky Huang , Kathryn Matt , Neerav Monga , Thomas Prebet , Thomas J. Prior , Bourras-Rezki Bengoudifa , Brenda Chyla , Carole Longson , Beate Wulff , Reshma Patel , Daniel Lopes de Menezes

The standardization and implementation of new endpoints are crucial for the development of novel therapeutic agents. These endpoints help streamline clinical development while maintaining high standards of care for innovative treatments, ultimately leading to improved patient outcomes. 

Clin Res Oncol, 2026, Volume 2, Issue 1, p1-11 | DOI: 10.46439/Oncology.2.009

Commentary Open Access

Pancreatic cancer therapy in the era of precision oncology

Sakarie Mustafe Hidig

Pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDAC), remains one of the most lethal malignancies, characterized by late diagnosis, aggressive tumor biology, and profound resistance to conventional therapies. Despite advances in surgical techniques and combination chemotherapy regimens such as FOLFIRINOX and gemcitabine-based therapies, survival outcomes remain poor, with five-year survival rates barely exceeding 10%. 

Clin Res Oncol, 2026, Volume 2, Issue 1, p12-17 | DOI: